Research and development (R&D) are the backbone of the cancer treatment market. Companies invest billions of dollars in R&D to discover, test, and bring new drugs to market. The lengthy and costly process of clinical trials, which includes phases I, II, and III, is essential for proving the safety and efficacy of new treatments. Breakthroughs in molecular biology and genomics have recently accelerated progress, leading to the development of targeted therapies that offer more personalized treatment options.
